Vaccines against pandemic influenza: What can be done before the next pandemic?

Pediatric Infectious Disease Journal

Volumn 27, Issue SUPPL. 10, 2008, Pages

  Huber, Victor C ^a   McCullers, Jonathan A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Adjuvant; Immunity; Influenza; Pandemic; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS HEMAGGLUTININ;

ARTICLE; ECONOMICS; EPIDEMIC; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; DISEASE OUTBREAKS; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED;

EID: 56149109467     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318168b749     Document Type: Conference Paper

References (41)

1. Webster RG, Bean WJ, Gorman OT, et al. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992;56:152-179.
2. Fouchier RA, Munster V, Wallensten A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol. 2005;79:2814-2822. (Pubitemid 40270559)
3. Kilbourne ED. Influenza pandemics in perspective. JAMA. 1977;237:1225-1228. (Pubitemid 8064274)
4. Webster RG, Laver WG. The origin of pandemic influenza. Bull World Health Organ. 1972;47:449-452.
5. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. Lancet. 1933;2:66-68.
6. Francis T Jr. Vaccination against influenza. Bull World Health Organ. 1953;8:725-741.
7. Davenport FM, Hennessy AV, Brandon FM, et al. Comparisons of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinins. J Lab Clin Med. 1964;63:5-13.
8. Bachmayer H. Selective solubilization of hemagglutinin and neuraminidase from influenza viruses. Intervirology. 1975;5:260-272.
9. Brady MI, Furminger IG. A surface antigen influenza vaccine. I. Purification of haemagglutinin and neuraminidase proteins. J Hyg (Lond). 1976;77:161-172.
10. Laver WG, Webster RG. Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine. Virology. 1976;69:511-522.
11. Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1-42.
12. Maassab HF. Adaptation and growth characteristics of influenza virus at 25 degrees C. Nature. 1967;213:612-614.
13. Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis. 2004;39:920-927. (Pubitemid 39313444)
14. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003;21:1769-1775. (Pubitemid 36398371)
15. Manzoli L, Schioppa F, Boccia A, et al. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J. 2007;26:97-106. (Pubitemid 46183358)
16. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168-175. (Pubitemid 30470986)
17. Note for guidance on harmonisation of requirements for influenza vaccines [Committee for Proprietary Medicinal Products web site]. 1997. Available at: http://www.emea.eu.int/pdfs/human/bwp/021496en.pdf. Accessed August 7, 2007.
18. Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21:1776-1779. (Pubitemid 36398372)
19. Fedson DS. Vaccine development for an imminent pandemic: why we should worry, what we must do. Hum Vaccin. 2006;2:38-42. (Pubitemid 43667665)
20. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine. 2007; 25:3752-3762. (Pubitemid 46589757)
21. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol. 1999;17:1075-1081. (Pubitemid 29533545)
22. Davenport FM, Hennessy AV, Askin FB. Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J Immunol. 1968;100:1139-1140.
23. Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA. 2004;101: 1356-1361. (Pubitemid 38182693)
24. Meijer A, Bosman A, van de Kamp EE, et al. Measurement of antibodies to avian influenza virus A(H7N7) in humans by hemagglutination inhibition test. J Virol Methods. 2006;132:113-120. (Pubitemid 43220169)
25. Hehme N, Engelmann H, Kuenzel W, et al. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 2004;103:163-171. (Pubitemid 38649075)
26. Hehme N, Engelmann H, Kunzel W, et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol. 2002;191:203-208. (Pubitemid 35435768)
27. Meiklejohn G. Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982. J Infect Dis. 1983;148:775-784. (Pubitemid 14244262)
28. Stephenson I, Nicholson KG, Gluck R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet. 2003;362:1959-1966. (Pubitemid 37548419)
29. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006;43:1135-1142. (Pubitemid 44632795)
30. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 2001;357:1937-1943. (Pubitemid 32568336)
31. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine. 2003;21:1687-1693. (Pubitemid 36287599)
32. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis. 2005;191:1210-1215.
33. Vaccine adjuvant system technology: background information [Glaxo-SmithKline Biologicals web site].2007. Available at: http://www.gsk.com/ media/flu/flu-adjuvant.pdf. Accessed August 7, 2007.
34. Osterhaus AD. Pre- or post-pandemic influenza vaccine? Vaccine. 2007; 25:4983-4984. (Pubitemid 46881267)
35. Suguitan AL Jr, McAuliffe J, Mill KL, et al. Live, attenuated influenza A H5N1 candidates provide broad cross-protection in mice and ferrets. PLoS Med. 2006;3:e360.
36. Schultz-Cherry S, McCullers JA. A step closer to meeting the threat of avian influenza. PLoS Med. 2006;3:e375.
37. Laver G, Garman E. Pandemic influenza: its origin and control. Microbes Infect. 2002;4:1309-1316. (Pubitemid 35356457)
38. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354:1343-1351.
39. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006;367:1657-1664. (Pubitemid 43744370)
40. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006;368:991-997. (Pubitemid 44353667)
41. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 2001;19:1732-1737. (Pubitemid 32175735)